North America Drug Discovery Market Forecast 2022-2030
Description
North America Drug Discovery Market Forecast 2022-2030
KEY FINDINGS
The North America drug discovery market is estimated to register a CAGR of 6.14% during the forecast period, 2022-2030. The surging demands are accredited to the growing prioritization of several therapeutic areas like rare diseases and women’s health.
REGIONAL INSIGHTS
The United States and Canada are assessed for the North America drug discovery market growth analysis. In Canada, the drug discovery and development market is comparatively small but is projecting gradual growth in terms of relevance and developments at multiple levels. For instance, Sunshine Biopharma, a pharmaceutical company in Canada, is engaged in the research, development, and commercialization of antiviral and oncology drugs.
Also, several Canadian-based biotechnology companies’ and academic institutions’ inventions and concepts have facilitated the development of essential drug delivery products that have improved the landscape of drug therapy in treating cancer and infectious diseases. Additionally, through partnerships, pharmaceutical companies’ extensive R&D activities enable additional investments in small and medium-sized enterprises (SMEs) and venture funds. Besides, pharmaceutical sales in Canada doubled between 2001 and 2015, with hospitals and retail sales representing 12.5% and 87.5% of the total pharmaceutical sales, respectively. Such developments contribute to market growth.
COMPETITIVE INSIGHTS
Some of the leading companies in the market are Icon Plc, Merck & Co Inc, Johnson & Johnson, IQVIA Holdings Inc, etc.
Our report offerings include:
Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation cater to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
KEY FINDINGS
The North America drug discovery market is estimated to register a CAGR of 6.14% during the forecast period, 2022-2030. The surging demands are accredited to the growing prioritization of several therapeutic areas like rare diseases and women’s health.
REGIONAL INSIGHTS
The United States and Canada are assessed for the North America drug discovery market growth analysis. In Canada, the drug discovery and development market is comparatively small but is projecting gradual growth in terms of relevance and developments at multiple levels. For instance, Sunshine Biopharma, a pharmaceutical company in Canada, is engaged in the research, development, and commercialization of antiviral and oncology drugs.
Also, several Canadian-based biotechnology companies’ and academic institutions’ inventions and concepts have facilitated the development of essential drug delivery products that have improved the landscape of drug therapy in treating cancer and infectious diseases. Additionally, through partnerships, pharmaceutical companies’ extensive R&D activities enable additional investments in small and medium-sized enterprises (SMEs) and venture funds. Besides, pharmaceutical sales in Canada doubled between 2001 and 2015, with hospitals and retail sales representing 12.5% and 87.5% of the total pharmaceutical sales, respectively. Such developments contribute to market growth.
COMPETITIVE INSIGHTS
Some of the leading companies in the market are Icon Plc, Merck & Co Inc, Johnson & Johnson, IQVIA Holdings Inc, etc.
Our report offerings include:
Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation cater to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
162 Pages
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Key Drivers
- 3.1.1. Growing R&D For Tackling Several Diseases
- 3.1.2. Technological Advancements
- 3.2. Key Restraints
- 3.2.1. Extensive Time-consuming Process
- 3.2.2. Highly Regulated Market
- 3.2.3. Project Feasibility And Success Rate
- 4. Key Analytics
- 4.1. Impact Of Covid-19 On Drug Discovery Market
- 4.2. Key Market Trends
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Buyers Power
- 4.3.2. Suppliers Power
- 4.3.3. Substitution
- 4.3.4. New Entrants
- 4.3.5. Industry Rivalry
- 4.4. Opportunity Matrix
- 4.5. Drug Discovery And Development Process
- 4.5.1. Drug Discovery And Development
- 4.5.2. Preclinical Research
- 4.5.3. Clinical Research
- 4.5.4. Regulatory Authority Review
- 4.5.5. Post Market Safety Monitoring
- 4.6. Regulatory Framework
- 5. Market By Drug Type
- 5.1. Small Molecule Drug
- 5.2. Biologic Drug
- 6. Market By Service
- 6.1. Chemical Services
- 6.2. Drug Metabolism And Pharmacokinetics Services
- 6.3. Biological Services
- 6.4. Other Pharmaceutical Services
- 7. Market By End-user
- 7.1. Pharmaceutical Companies
- 7.2. Contract Research Organizations
- 7.3. Research Institutes
- 7.4. Other End-users
- 8. Market By Technology
- 8.1. High Throughput Screening
- 8.2. Spectroscopy
- 8.3. Combinatorial Chemistry
- 8.4. Biochips
- 8.5. Pharmacogenomics And Pharmacogenetics
- 8.6. Bioinformatics
- 8.7. Metabolomics
- 8.8. Nanotechnology
- 8.9. Other Technologies
- 9. Geographical Analysis
- 9.1. North America
- 9.1.1. Market Size & Estimates
- 9.1.2. Key Growth Enablers
- 9.1.3. Key Challenges
- 9.1.4. Key Players
- 9.1.5. Country Analysis
- 9.1.5.1. United States
- 9.1.5.2. Canada
- 10. Competitive Landscape
- 10.1. Key Strategic Developments
- 10.1.1. Mergers & Acquisitions
- 10.1.2. Product Launches & Developments
- 10.1.3. Partnerships & Agreements
- 10.1.4. Business Expansions & Divestitures
- 10.2. Company Profiles
- 10.2.1. Agilent Technologies Inc
- 10.2.2. Astrazeneca Plc
- 10.2.3. Bayer Ag
- 10.2.4. Charles River Laboratories International Inc
- 10.2.5. Eli Lilly And Company
- 10.2.6. Evotec Se
- 10.2.7. Glaxosmithkline Plc
- 10.2.8. Icon Plc
- 10.2.9. Iqvia Holdings Inc
- 10.2.10. Johnson & Johnson
- 10.2.11. Merck & Co Inc
- 10.2.12. Novartis Ag
- 10.2.13. Pfizer Inc
- 10.2.14. Roche Ag
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.